- CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies.
CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies.
Scientific reports (2017-04-14)
Jie Ma, Huan Li, Xiangnan Hu, Lu Yang, Qi Chen, Congli Hu, Zhihao Chen, Xiaoyan Tian, Yang Yang, Ying Luo, Run Gan, Junqing Yang
PMID28406239
ABSTRACT
Dipeptidyl peptidase IV (DPP-IV) inhibitor has been expected to be a new class of anti-diabetic agent. The present study was designed to characterize the pharmacological profiles of CMD-05, a novel DPP-IV inhibitor discovered in our laboratory, in vitro and in vivo. The IC
MATERIALS